70 Usha Verma and Neil Verma
[98] Park H, Seok JM, Yoon BS, Seong SJ, Kim JY, Shim JY, Park CT.
Effectiveness of high-dose progestin and long-term outcomes in young
women with early-stage, well-differentiated endometrioid
adenocarcinoma of uterine endometrium. Arch Gynecol Obstet.
2012;285:473–478.
[99] Nelson AL. Counseling issues and management of side effects for
women using depot medroxyprogesterone acetate contraception. J
Reprod Med. 1996; 41:391–400.
[100] Erkkola R, Landgren BM. Role of progestins in contraception. Acta
Obstet Gynecol Scand. 2005;84):207-216.
[101] Akhter H, Dunson TR, Amatya RN Begum K, Chowdhury T, Dighe N,
et al. A five-year clinical evaluation of Norplant® contraceptive
subdermal implants in Bangladeshi acceptors. Contraception. 1993; 47:
569 - 592.
[102] Du MK, Zheng HM, Chen HC, Chow LP. Study of Norplant® implants
in Shanghai: three-year experience. Int. J. GynecoL Obstet. 1990; 33:
345 - 357.
[103] Gerber S, Westhoff C, Lopez M, Gordon L. Use of Norplant® implants
in a New York City clinic population. Contraception. 1994; 49: 557-
564.
[104] Gu-Juan G, Ming-kun D, Ling-De Z. Liu YL, Wang SH, Sivin I. A 5-
year evaluation of Norplant® contraceptive implants in China. Obstet.
Gynecol. 1994; 83:673-678.
[105] Noerpramana NP. A cohort study of Norplant* implant: side-effects and
acceptance. Adv. Contracept. 1995;11:97-114.
[106] Pasquale SA, Knuppel RA, Owens G, Bachmann GA. Irregular
bleeding, body mass index and coital frequency in Norplant®
contraceptive users. Contraception.1994;50: 109-116.
[107] Sivin I. Contraception with Norplant® implants. Hum. Reprod, 1994 ;
9:1818-1826.
[108] Berlex Pharmaceuticals. [Accessed on June 24, 2009];Mirena ®
Physician Information. 2008 Jul; Available from: http://berlex.bayer
health-care.com/html/products/pi/Mirena_PI.pdf.
[109] ACOG Committee on Practice Bulletins-Gynecology. ACOG practice
bulletin. Clinical management guidelines for obstetrician-gynecologists.
Number 59, January 2005. IUD. Obstet Gynecol. 2005;105:223–232.
[110] Baldaszti E, Wimmer-Puchinger B, Löschke K. Acceptability of the
long-term contraceptive levonorgestrel-releasing intrauterine system
(Mirena): a 3-year follow-up study. Contraception. 2003;67:87–91.